Friday , December 14 2018
Breaking News
Home / BUSINESS / Lupin launches generic Atovaquone Oral Suspension USP in US

Lupin launches generic Atovaquone Oral Suspension USP in US

Lupin has launched Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron oral suspension 750 mg/5 ml. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately $119 million in the US (IQVIA MAT September 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Loading...